Aug 24, 2013 - temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. Despite technical ...
M. Balducci1 · A. Fiorentino2 · P. De Bonis3 · S. Chiesa1 · A. Mangiola3 · G.C. Mattiucci1 · G.R. D’Agostino1 · V. Frascino1 · G. Mantini1 · A.R. Alitto1 · C. Colosimo4 · C. Anile3 · V. Valentini1 1 Department of Radiation Oncology, Catholic University of the Sacred Heart, Rome 2 Department of Radiation Oncology, IRCCS/CROB, Rionero in Vulture 3 Department of Neurosurgery, Catholic University of the Sacred Heart, Rome 4 Department of Radiology, Catholic University of the Sacred Heart, Rome
Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma Hypotheses based on two prospective phase II trials
Despite technical advances in surgery and radiotherapy (RT), patients with glioblastoma (GBM) generally have a very poor prognosis, with a median survival of 12– 14 months [2, 26]. Younger age, high Karnofsky Performance Score (KPS), higher surgical extent, additional adjuvant treatments and methylguanine DNA methyltransferase (MGMT) methylation are associated with better outcome [9, 11, 21]. Surgery followed by RT with concomitant and adjuvant temozolomide (TMZ)based chemotherapy (CH) has become the standard of care for newly diagnosed GBM [2, 26]. In a randomized trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC), Stupp et al. [26] showed that patients who received adjuvant chemoradiotherapy (TMZ 75 mg/ m2/day) followed by six cycles of TMZ (150–200 mg/ m2, 5 days every 28 days) had better survival rates compared to patients receiving adjuvant RT alone (2-year survival rates: 26 vs. 10%, respectively; p70; WBC count >3.5×10 3 /ul; platelet count >150×103/ul; bilirubin and creatinine levels less than 1.5 times the upper limit of normal and aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase levels
